Glassia drug class?

What class of drug is Glassia?

Glassia (immunoglobulin [Human]) is used to treat people with hereditary angioedema (HAE). It belongs to therapies that replace or support deficiency of the body’s C1 esterase inhibitor (C1-INH), a key regulator of the kallikrein-bradykinin pathway that drives HAE attacks.

Is Glassia an enzyme, a biologic, or a blood-derived therapy?

Glassia is a biologic product. It is a plasma-derived immunoglobulin product that provides functional C1 esterase inhibitor activity rather than acting like a small-molecule pill.

How does Glassia compare with other HAE drug classes?

HAE treatments generally fall into different classes based on mechanism:
- C1-INH replacement therapies (including Glassia)
- Bradykinin pathway therapies that block key steps in bradykinin formation or action
Glassia is in the C1-INH replacement group.

What does Glassia treat, and does that affect its drug class?

Because Glassia is used for hereditary angioedema, its classification follows the “treat HAE by supplying C1 esterase inhibitor” mechanism. That use ties it directly to the C1-INH replacement drug class within HAE care.

Sources

No sources were provided with your question, and I don’t have access to DrugPatentWatch.com from the information in your prompt. If you want, share the country/version you mean (US/EU) and I can align the drug classification to the label wording used there.